Bioventus

Bioventus

Yahoo Finance • 2 months ago

Consumer Sentiment Just Crashed Below the Recession Threshold. These 3 Defensive Stocks Under $25 Are Built for What Comes Next

Quick Read Consumer sentiment has collapsed to levels unseen in years, pushing investors toward defensive healthcare and consumer staples names with pricing power and recurring revenue models. The analyst who called NVIDIA in 2010 just na... Full story

Yahoo Finance • 2 months ago

Bioventus Q1 Earnings Call Highlights

Bioventus logo Bioventus (NASDAQ:BVS) reported first-quarter 2026 results that management said put the company “off to a strong start” as it increased investment in several growth drivers while still expanding profitability and cash gener... Full story

Yahoo Finance • 2 months ago

Bioventus Reports First Quarter Financial Results

Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15 per diluted share compared to $0.08 per d... Full story

Yahoo Finance • 2 months ago

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter... Full story

Yahoo Finance • 3 months ago

ASX Penny Stocks To Watch In April 2026

The Australian market is experiencing a surge with the ASX 200 futures showing a significant hike, buoyed by renewed global optimism following geopolitical developments. In such dynamic conditions, investors often look beyond established g... Full story

Yahoo Finance • 4 months ago

Noteworthy Thursday Option Activity: ALK, BVS, UPS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alaska Air Group, Inc. (Symbol: ALK), where a total volume of 20,296 contracts has been traded thus far today, a contract... Full story

Yahoo Finance • 4 months ago

Bioventus Inc. Q4 2025 Earnings Call Summary

Bioventus Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Transformation Drivers Management characterizes the company as having completed a three-year transformation, shifting from foundational stabilization to an 'ex... Full story

Yahoo Finance • 7 months ago

Bravura Solutions And 2 Other ASX Penny Stocks To Watch

The Australian stock market is showing modest gains, buoyed by a late Christmas rally in the U.S., with precious metals and the Australian dollar also enjoying strong performances. In this context, investors might find value in exploring p... Full story

Yahoo Finance • 8 months ago

Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference

DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Pip... Full story

Yahoo Finance • 10 months ago

Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will part... Full story

Yahoo Finance • 11 months ago

ASX Penny Stocks Spotlight: Barton Gold Holdings And Two More Hidden Gems

Australian shares are showing signs of recovery, with ASX futures gaining as traders focus on the upcoming inflation update and global economic developments. While the term "penny stocks" might seem outdated, these often smaller or newer c... Full story

Yahoo Finance • 11 months ago

Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT

Bioventus Inc. (NASDAQ:BVS) is one of the best medical device stocks to buy according to analysts. On August 7, Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Bioventus Inc. (NASDAQ:BVS) and set a price target of $15.0... Full story

Yahoo Finance • 11 months ago

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference

DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a f... Full story

Yahoo Finance • 11 months ago

Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance

Earnings Call Insights: Bioventus Inc. (BVS) Q2 2025 MANAGEMENT VIEW * Robert E. Claypoole, President and CEO, highlighted, "Second quarter revenue of $148 million was in line with our expectations and reflected the strength of our por... Full story

Yahoo Finance • 11 months ago

Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity

DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit... Full story

Yahoo Finance • 11 months ago

Bioventus receives FDA clearance for two pain management devices

DURHAM, N.C. - Bioventus Inc. (NASDAQ:BVS), a $452 million medical device company with annual revenues of $567 million and impressive gross margins of 67%, announced Wednesday it has received U.S. Food and Drug Administration 510(k) cleara... Full story

Yahoo Finance • 11 months ago

Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products

DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances f... Full story

Yahoo Finance • 11 months ago

Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025

DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter... Full story

Yahoo Finance • last year

Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased 86.3%Provides full-year 2025 financial g... Full story

Yahoo Finance • last year

Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter... Full story